Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product, Feraccru®, is a novel oral ferric iron therapy that is approved and marketed in the European Union for the treatment of Iron Deficiency (ID) with or without anaemia in adults and in Switzerland for the treatment of Iron Deficiency Anaemia (IDA) in adults with inflammatory bowel disease (IBD).
Find out moreRT @Edison_Inv_Res: Executive interview with #Dr_Sean_Conroy, healthcare analyst at #Edison, talking about @ShieldTx https://t.co/aXqJmdDz3…
RT @EdisonHealth: Executive interview with #Dr_Sean_Conroy, healthcare analyst at #Edison, talking about @ShieldTx https://t.co/yydvMRP648…
RT @WalbrookPR: **LISTEN** Bitesize briefing – Shield Therapeutics (AIM: #STX): Healthcare analyst Dr Sean Conroy provides an overview of @…
